4D Molecular Therapeutics stock price, funding rounds, valuation and financials

4D Molecular Therapeutics has raised $100 m in total funding. 4D Molecular Therapeutics annual revenue was $14.13 m in FY 2018

$14.1 M

4D Molecular Therapeutics Revenue FY, 2018
4D Molecular Therapeutics Revenue growth (FY, 2017 - FY, 2018), %144%
4D Molecular Therapeutics Net income (FY, 2018)-9.6 M
4D Molecular Therapeutics EBIT (FY, 2018)-10.4 M
4D Molecular Therapeutics Cash, 30-Jun-201972.9 M

4D Molecular Therapeutics Funding

Summary Metrics

Founding Date

2013

4D Molecular Therapeutics total Funding

$100 m

4D Molecular Therapeutics latest funding size

$90 m

Time since last funding

a year ago

4D Molecular Therapeutics investors

4D Molecular Therapeutics's latest funding round in September 2018 was reported to be $90 m. In total, 4D Molecular Therapeutics has raised $100 m

4D Molecular Therapeutics Capital Raised

Embed Graph

4D Molecular Therapeutics Revenue Breakdown

Embed Graph

4D Molecular Therapeutics revenue breakdown by business segment: 63.6% from Collaboration and Research Revenue (Related Parties) and 36.4% from Collaboration and Research Revenue

4D Molecular Therapeutics Income Statement

Annual

USDFY, 2017FY, 2018

Revenue

5.8m14.1m

Revenue growth, %

144%

R&D expense

13.6m18.4m

General and administrative expense

3.5m6.2m

Operating expense total

17.1m24.5m

EBIT

(11.3m)(10.4m)

EBIT margin, %

(195%)(74%)

Interest income

89.0k850.0k

Net Income

(11.2m)(9.6m)

4D Molecular Therapeutics Balance Sheet

Annual

USDFY, 2017FY, 2018

Cash

23.9m91.8m

Accounts Receivable

321.0k1.1m

Current Assets

24.5m94.1m

PP&E

2.7m2.5m

Total Assets

27.3m97.0m

Accounts Payable

460.0k954.0k

Current Liabilities

5.9m8.1m

Common Stock

1.0k1.0k

Preferred Stock

18.5m103.0m

Additional Paid-in Capital

884.0k2.4m

Retained Earnings

(20.5m)(30.0m)

Total Equity

(19.6m)(27.6m)

Financial Leverage

-1.4 x-3.5 x

Quarterly

USDQ2, 2019

Cash

72.9m

Accounts Receivable

1.2m

Current Assets

75.4m

PP&E

4.0m

Total Assets

80.5m

Accounts Payable

1.1m

Current Liabilities

8.6m

Common Stock

1.0k

Preferred Stock

103.0m

Additional Paid-in Capital

3.9m

Retained Earnings

(46.2m)

Total Equity

(42.3m)

Financial Leverage

-1.9 x

4D Molecular Therapeutics Cash Flow

Annual

USDFY, 2017FY, 2018

Net Income

(11.2m)(9.6m)

Depreciation and Amortization

626.0k697.0k

Accounts Receivable

(320.0k)(803.0k)

Accounts Payable

(114.0k)438.0k

Cash From Operating Activities

8.2m(16.3m)

Purchases of PP&E

(573.0k)(414.0k)

Cash From Investing Activities

7.7m(414.0k)

Cash From Financing Activities

16.0k84.6m

Net Change in Cash

15.9m67.9m

Quarterly

USDQ2, 2018Q2, 2019

Net Income

(5.2m)(16.5m)

Depreciation and Amortization

341.0k406.0k

Accounts Receivable

(1.4m)(37.0k)

Accounts Payable

559.0k62.0k

Cash From Operating Activities

(6.4m)(17.2m)

Purchases of PP&E

(33.0k)(1.7m)

Cash From Investing Activities

(33.0k)(1.7m)

Cash From Financing Activities

20.0k(62.0k)

Net Change in Cash

(6.4m)(18.9m)

4D Molecular Therapeutics Ratios

USDY, 2019

Financial Leverage

-1.9 x

4D Molecular Therapeutics Operating Metrics

Oct, 2019

Drugs in Development

6

Industry Partners

2

Patents (US)

1

Patient Advocacy Partners

3

Preclinical Phase Products

6